Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis
Ran Gu(Monash University), Eric F. Morand(Novartis (Switzerland)), Leilani L. Santos(Royal Women's Hospital), Günter Fingerle‐Rowson(University Hospital Cologne), Jiake Xu(Shenzhen Institutes of Advanced Technology), Preetinder P. Singh, Devi Ngo(Monash Medical Centre), Julian M.W. Quinn(Cancer Institute of New South Wales), Richard Bucala(Yale University)
Cited by 52
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites
|The Journal of Immunology|2001|957
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726